luspatercept for the treatment of patients with lower-risk mds and esa failure
Published 1 year ago • 966 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
0:45
non-pharmaceutical interventions for patients with mpns and other hematological malignancies
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
3:40
no sound reblozyl® (luspatercept-aamt) for anaemia
-
7:18
how might luspatercept benefit patients with myelofibrosis?
-
5:42
promising therapeutic efficacy of ebv-specific t-cell immunotherapy tabelecleucel in ptld
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
1:31
overall survival of patients following treatment with luspatercept in the medalist trial
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
2:11
new therapeutic options for low-risk mds
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response